Prosensa maintains sunny outlook as drisapersen data trickle through
This article was originally published in Scrip
Prosensa has reaffirmed its faith in its investigational Duchenne muscular dystrophy (DMD) therapy drisapersen, with updated Phase II results that it says lend further support to the idea that patients need to be treated earlier and for longer for best effect in delaying progression in the deadly disease.
You may also be interested in...
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.